Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Philadelphia-based Carisma Therapeutics has raised $53 million in series A financing to develop new cancer cell therapies based on research from University of Pennsylvania scientists. Unlike the two commercial CAR-T cancer cell therapies, which use engineered T cells, Carisma’s therapy uses macrophages, a different kind of immune cell that eats other cells through phagocytosis. By adding chimeric antigen receptor (CAR) proteins, Carisma hopes to create macrophages that will chow down on cancer. AbbVie Ventures and HealthCap led the funding.
This article has been sent to the following recipient: